Group 1 - C Weigao (603014) saw a first-day increase of 56.26%, with a turnover rate of 69.71% and a transaction volume of 1.15 billion yuan [2] - The stock had a net inflow of 178 million yuan from major funds on its first trading day, with large orders contributing 130 million yuan [3] - The stock's first-day financing amount was 39.74 million yuan, accounting for 3.46% of the total trading volume, with a latest financing balance of 34.33 million yuan, representing 2.18% of the circulating market value [2][3] Group 2 - C Weigao specializes in the research, production, and sales of blood purification medical products [3] - On the first trading day, the top five trading departments on the dragon and tiger list had a total transaction of 175 million yuan, with a net selling of 10.46 million yuan [3] - The financing balance for C Weigao on its first day was 34.33 million yuan, with no short selling balance recorded [3]

IPO Review and Registration Progress - Jiangsu Youli Intelligent Equipment Co., Ltd. has passed the IPO review, focusing on the sustainability of its performance and R&D capabilities, with projected revenues of 433 million yuan, 658 million yuan, and 729 million yuan from 2022 to 2024, and net profits of 42.19 million yuan, 78.17 million yuan, and 90.05 million yuan respectively [2] - Mingguang Rier Jinda Technology Co., Ltd. has had its IPO application accepted, aiming to raise approximately 335 million yuan, with projected revenues of 467 million yuan in 2024, reflecting a 1.9% increase, while net profit is expected to decline by 8.04% to 85 million yuan [3] - Huadian New Energy Group Co., Ltd. has received approval for its IPO registration, planning to raise 18 billion yuan for renewable energy projects, with total assets exceeding 365 billion yuan [4] New Stock Subscription and Listing Dynamics - Two new stocks, Weigao Blood Purification and Taili Technology, are set to be listed, with Weigao's initial price at 26.5 yuan per share and a market performance increase of 56.25% on the first day, while Taili's price is 17.05 yuan per share with a remarkable 218.48% increase on its debut [6][7] - Upcoming subscriptions include Guxi Down Material and Zhongce Rubber, with a total expected fundraising of 5.564 billion yuan, and Zhongce Rubber aiming to raise 4.85 billion yuan for production base expansions [8][9] Policy and Regulatory Developments - Guangzhou has introduced measures to support the elderly care industry in expanding direct financing channels through listings and bond issuance [10][11] - The China Securities Regulatory Commission has announced new fundraising regulations effective June 15, 2025, aimed at enhancing the safety and efficiency of fundraising activities [12] - The CSRC plans to intensify enforcement against fraudulent issuance cases in 2024, with significant penalties imposed on companies for providing false financial data [13]

Core Viewpoint - The new share issuance results of Weigao Blood Purification indicate a strong interest from online investors, with a total subscription amount of 707.77 million yuan and a low abandonment rate of 0.544% [1][2][3]. Summary by Category Subscription Details - Online investors subscribed for 26,708,400 shares, amounting to 707.77 million yuan, while offline investors subscribed for 12,512,100 shares, totaling 331.57 million yuan [2][3]. - The total number of shares issued was 41,139,400, with an issuance price of 26.5 yuan per share [3]. Abandonment Rates - The online abandonment quantity was 146,100 shares, with an abandonment amount of 3.87 million yuan, while offline abandonment was minimal at 695 shares, amounting to 18,400 yuan [1][2]. - The overall abandonment rate for online subscriptions was 0.544%, with the abandonment amount being 387.16 thousand yuan [1][3]. Market Context - In the context of recent new share issuances, Weigao Blood Purification ranked among the top in terms of abandonment quantity and rate, with notable competitors including Tian You Wei and Jiang Shun Technology [3]. - The online issuance final winning rate was 0.03215719%, and the strategic allocation was 1,772,100 shares [3].

Group 1 - The company, Weigao Blood Purification, has initiated a public offering with a total issuance of 41.1394 million shares, including 11.1075 million shares for online subscription at a price of 26.50 yuan per share, with an issuance price-to-earnings ratio of 24.82 times [1][3] - The maximum subscription limit for a single account is set at 11,000 shares, with subscriptions required to be in multiples of 500 shares [1][3] - The funds raised will be allocated to various projects, including 400 million yuan for working capital, 342 million yuan for intelligent production construction, and 28.5 million yuan for a new high-performance consumables R&D center [3] Group 2 - The company specializes in the research, production, and sales of medical products for blood purification [2] - Key financial indicators for the company show total assets of 69.90 billion yuan in 2024, a net profit of 4.49 billion yuan, and a basic earnings per share of 1.21 yuan [3]

Summary of Key Points Core Viewpoint - This week, three new stocks are available for subscription in the A-share market, including Hanbang Technology, Weigao Blood Purification, and Taili Technology [1][2]. Group 1: Hanbang Technology - Hanbang Technology is a leading company in chromatography equipment in China, with a subscription code of 787755 and an issue price of 22.77 yuan per share, with a P/E ratio of 26.35 times [3][6]. - The total number of shares issued is 22 million, with 5.28 million shares available for online subscription. The maximum subscription limit for investors is 5,000 shares, requiring a market value of 50,000 yuan in the Shanghai market [3][6]. - The company’s revenue is projected to grow from 482 million yuan in 2022 to 691 million yuan in 2024, with net profits increasing from 38.56 million yuan to 79.34 million yuan during the same period [7][10]. - Major clients include domestic pharmaceutical companies and international clients such as INTECH ANALYTICAL INSTRUMENTS and REETEC AS [7]. Group 2: Weigao Blood Purification - Weigao Blood Purification is a manufacturer of medical products for blood purification, with a subscription code of 732014. The total number of shares issued is 41.14 million, with 11.11 million shares available for online subscription [12][14]. - The company’s revenue is expected to rise from 3.426 billion yuan in 2022 to 3.604 billion yuan in 2024, with net profits increasing from 315.00 million yuan to 449.39 million yuan [12][14]. - Key clients include major pharmaceutical groups such as China National Pharmaceutical Group and China Resources Group [12]. Group 3: Taili Technology - Taili Technology focuses on new material research and vacuum technology applications, with a subscription code of 301595. The total number of shares issued is 27.07 million, with 6.90 million shares available for online subscription [17]. - The company’s revenue is projected to grow from 638 million yuan in 2022 to 1.020 billion yuan in 2024, with net profits increasing from 58.84 million yuan to 87.64 million yuan [17][18]. - Major clients include international retailers such as IKEA and Walmart, with Taili Technology being the exclusive supplier of vacuum bags for China's aerospace applications [17].